SOPHiA GENETICS Competitive Intelligence & Landscape

SOPHiA GENETICS is a leading biotechnology company founded in 2011 that specializes in data-driven medicine and precision healthcare. Headquartered in Rolle, Switzerland, with additional offices in Boston, Massachusetts, the company has established itself as a pioneer in utilizing artificial intelligence (AI) and advanced data analytics to transform patient diagnosis and treatment, particularly in genomics and radiomics (Wikipedia; sophiagenetics.com).

The company's core product, the SOPHiA DDM™ platform, is a cloud-native, SaaS solution that analyzes multimodal data—including genomics, radiomics, clinical, biological, and digital pathology data—to generate actionable insights for hospitals, laboratories, and biopharma institutions. This platform helps clinicians and researchers interpret complex biological data to improve outcomes in cancer, rare diseases, and other medical conditions (ir.sophiagenetics.com). SOPHiA GENETICS serves over 780 healthcare institutions worldwide and also collaborates with biopharma companies for AI-powered drug discovery and development (Result 2).

The company’s mission is to democratize data-driven medicine by expanding access to AI and genomic insights globally, driven by a vision to make a lasting positive impact on healthcare. With a workforce of over 400 employees, SOPHiA GENETICS emphasizes innovation, collaboration, and improving scientific outcomes through its advanced AI capabilities and comprehensive data analysis solutions (Result 1; Result 6). Its value proposition centers on transforming healthcare by making complex biological data accessible and actionable for clinicians and researchers worldwide.

SOPHiA GENETICS offers a range of products primarily focused on data-driven medicine and precision healthcare through their cloud-native platform, SOPHiA DDM™. As of early 2026, the company has not publicly disclosed specific pricing tiers or detailed product pricing plans on their main website or marketplace listings, but recent financial reports indicate a focus on scalable, enterprise-level solutions that support large healthcare networks and biopharma institutions (sophiahealth.ai, Microsoft Marketplace).

Their subscription models include a free trial offering limited features such as session recordings and post-session analytics, with paid plans like the Supercharge Basic and Enterprise tiers providing additional features such as automated notes, smart treatment plans, EHR integrations, and API access. The Basic plan costs $59/month or $468/year, with a discounted rate of $39/month or $390/year during limited-time offers, and includes 80 live sessions per month. The Enterprise plan is priced at $99/month or $948/year, with similar discounts, and offers advanced functionalities like in-session guidance and treatment planning (sophiahealth.ai).

Additionally, there is an Outcome Measurements Add-on available for $25/month or $10/month during promotional periods, which automates client assessments and progress tracking (sophiahealth.ai). Recent financial disclosures from SOPHiA GENETICS in 2026 reveal ongoing revenue growth and increased investment in scalable, AI-enhanced solutions, but specific recent changes to pricing strategies have not been explicitly detailed publicly (PR Newswire).

As of early 2026, SOPHiA GENETICS continues to demonstrate strong hiring activity, with recent job postings across multiple departments including engineering, AI and machine learning, operations, sales, and research (LinkedIn). The company is actively recruiting for roles in the United States, Europe, and Switzerland, indicating a strategic focus on expanding its global footprint and advancing its technological capabilities (Built In). Notably, SOPHiA GENETICS has been hiring for specialized roles such as bioinformaticians, clinical biomarker experts, and platform product managers, reflecting its emphasis on innovation in healthcare data and genomics.

In addition, the company announced a major expansion in the United States in February 2026, signing agreements with two significant health systems, which signals a focus on scaling its operations and integrating more deeply into the healthcare ecosystem (SOPHiA GENETICS News). There is no publicly available information on layoffs, suggesting that SOPHiA GENETICS is currently prioritizing growth and talent acquisition to support its strategic initiatives. Overall, these hiring patterns and expansion efforts indicate a company strategy centered on technological innovation, geographic expansion, and strengthening its position as a leader in data-driven healthcare solutions.

As of early 2026, SOPHiA GENETICS reported strong financial performance for 2025, with revenues reaching approximately $77 million, representing a 19% increase year-over-year. The company’s preliminary guidance for 2026 projects revenues between $92 million and $94 million, indicating a growth rate of about 20% to 22% (sophiagenetics.com).

In terms of profitability, SOPHiA GENETICS experienced net losses in 2025, with an IFRS net loss of $79 million, which increased by 26% compared to the previous year. Despite these losses, the company demonstrated operational growth through increased analysis volume, performing over 391,000 analyses in 2025, a new record (PRNewswire).

Regarding fundraising and valuation, SOPHiA GENETICS had a valuation of approximately $268 million based on valuation multiples, with a reported revenue of $81 million in the last twelve months and an EBITDA of around -$40 million, reflecting its growth stage and ongoing investments (multiples.vc). The company has also been active in M&A and strategic partnerships, leveraging its AI-driven platform to expand its market presence and capabilities (sophiagenetics.com). Overall, SOPHiA GENETICS continues to demonstrate solid revenue growth and operational scale despite ongoing net losses, positioning it as a key player in the precision medicine sector.

SOPHiA GENETICS actively participates in a variety of events, including conferences, webinars, and community initiatives, primarily focused on healthcare innovation and data-driven medicine. Notably, the company hosts and attends investor relations events such as earnings calls and strategic investor days, with recent examples including the Q3 2025 Earnings Call and the inaugural Investor Day in September 2022, where they outlined their strategic vision and partnerships (ir.sophiagenetics.com, PRNewswire).

In addition to investor-focused events, SOPHiA GENETICS engages in scientific and medical conferences. For instance, they announced updates on SOPHiA UNITY at ESMO 2024, a global oncology research initiative, demonstrating their involvement in major medical congresses that focus on cancer research and precision medicine (ir.sophiagenetics.com).

While specific details on webinars and community events are not extensively documented, the company's participation in high-profile healthcare events and strategic conferences highlights their active role in fostering innovation, collaboration, and knowledge sharing within the healthcare and genomics sectors.